公开(公告)号：US20190016775A1

公开(公告)日：2019-01-17

申请号：US16029878

申请日：2018-07-09

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Helen Kim Cho ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Marianne Marcela Andrea Martinic

IPC: C07K14/705 ,  C12N9/12

Abstract: The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US11058753B2

公开(公告)日：2021-07-13

申请号：US16252239

申请日：2019-01-18

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  C12N15/62 ,  A61K48/00 ,  A61K31/711

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US20170202938A1

公开(公告)日：2017-07-20

申请号：US15407890

申请日：2017-01-17

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/585 ,  A61K2039/70

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US20220323558A1

公开(公告)日：2022-10-13

申请号：US17319395

申请日：2021-05-13

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  A61K48/00

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US20190142918A1

公开(公告)日：2019-05-16

申请号：US16252239

申请日：2019-01-18

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  A61K48/00

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US10251944B2

公开(公告)日：2019-04-09

申请号：US15407890

申请日：2017-01-17

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  A61K31/711 ,  C12N15/12 ,  C12N15/62 ,  A61K48/00

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.